Juravinski Cancer Centre
Juravinski Hospital
Hamilton, ON
Not yet accepting
QUINTESSENTIAL-2
Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
Accepting patients
Etentamig
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
AZD0305
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- GPRC5D
- Phase 1/2